Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROXYZINE vs Diphenhydramine
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hydroxyzine is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors in the gastrointestinal tract, blood vessels, and respiratory tract. It also exhibits sedative, anxiolytic, and antiemetic properties, possibly through central nervous system depression and anticholinergic effects.
Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.
Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitis,Anxiety and tension (as a short-term management in adults),Preoperative sedation and to reduce anxiety prior to surgery,Nausea and vomiting (off-label),Insomnia (off-label)
Allergic rhinitis,Urticaria,Pruritus,Insomnia (OTC sleep aid),Motion sickness,Parkinsonism (off-label for extrapyramidal symptoms)
25-100 mg orally 3-4 times daily; 50-100 mg IM every 4-6 hours as needed. Maximum oral dose: 600 mg/day in divided doses.
25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).
Terminal elimination half-life: 14-25 hours (mean ~20 h). In elderly or hepatic impairment, may be prolonged; antihistamine effect persists beyond half-life due to active metabolite.
Terminal elimination half-life 4-8 hours in adults; prolonged in hepatic impairment (up to 20 hours) and elderly.
Hydroxyzine is primarily metabolized by the liver via CYP3A4 and CYP2D6 isoenzymes. The major active metabolite is cetirizine, which is also a histamine H1 receptor antagonist.
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: administer every 24 hours. Not recommended for use in patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) due to increased risk of neurotoxicity.
No specific dose adjustment for GFR. Use with caution in severe renal impairment (Cr Cl <10 m L/min) due to potential accumulation; consider reducing dose or extending interval.
There is no FDA black box warning for hydroxyzine.
Hydroxyzine is generally considered low risk for teratogenicity. Animal studies have shown no consistent evidence of fetal harm. Human data are limited but do not indicate a significant increase in major malformations. In the first trimester, use only if clearly needed. In the second and third trimesters, there is a potential risk of neonatal respiratory depression, hypotonia, and withdrawal symptoms if used near term or in high doses. Avoid use during labor and delivery due to potential maternal hypotension and fetal effects.
First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second trimester: No known risk. Third trimester: Near term, high doses may cause oxytocin-like effects; once-daily antihistamine effect with minimal fetal risk. Avoid use during late third trimester due to potential for uterine hyperstimulation.
Hydroxyzine is a first-generation antihistamine with anxiolytic, sedative, and antiemetic properties. It is commonly used for pruritus, anxiety, and premedication. Avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, risk of confusion and falls is increased; consider alternative therapies. Hydroxyzine has anticholinergic effects; use cautiously in patients with glaucoma, urinary retention, or prostatic hyperplasia. Note that hydroxyzine can cause QT prolongation at high doses or in combination with other QT-prolonging drugs.
Diphenhydramine is a first-generation antihistamine with strong anticholinergic effects; avoid in elderly due to increased risk of confusion, falls, and urinary retention. Rapid IV administration can cause hypotension and arrhythmias; give slow IV push. Use with caution in patients with glaucoma, prostate hypertrophy, or asthma. Onset of sedation within 30-60 minutes; useful for acute dystonias (e.g., from antipsychotics) at 25-50 mg IM/IV. Not recommended for children <2 years due to risk of respiratory depression.
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Levomilnacipran."
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Desvenlafaxine."
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Milnacipran."
HYDROXYZINE and Diphenhydramine are distinct pharmacological agents. HYDROXYZINE belongs to the Antihistamine class and is primarily used for Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitisAnxiety and tension (as a short-term management in adults)Preoperative sedation and to reduce anxiety prior to surgeryNausea and vomiting (off-label)Insomnia (off-label). Diphenhydramine belongs to the Antihistamine class and is primarily used for Allergic rhinitisUrticariaPruritusInsomnia (OTC sleep aid)Motion sicknessParkinsonism (off-label for extrapyramidal symptoms). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. HYDROXYZINE carries a safety status of Category A/B, whereas Diphenhydramine safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2C9, and CYP2C19; undergoes N-demethylation and N-oxidation; first-pass metabolism is extensive.
Renal: approximately 70% as metabolites, less than 1% unchanged. Fecal/biliary: minor. Cetirizine (active metabolite) also renally eliminated.
Primarily renal (90-95% as metabolites, <5% unchanged). Minor biliary/fecal elimination (<5%).
93% bound to plasma proteins, primarily albumin.
98-99% bound, primarily to albumin.
16 L/kg (range 7-20 L/kg), indicating extensive tissue distribution; higher Vd suggests large extravascular binding.
Vd 3-5 L/kg (wide distribution, high tissue binding).
Oral: approximately 80%; IM: >80% (almost complete and rapid); IV: 100%.
Oral: 50-70% (first-pass metabolism). IM: 100% (assumed). IV: 100%.
Child-Pugh Class B: reduce dose by 50% and/or increase dosing interval to every 12-24 hours. Child-Pugh Class C: use with caution; consider alternative agent or reduce dose by 75% and administer every 24 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider 25% of usual dose or avoid.
Oral: 2 mg/kg/day in divided doses every 6-8 hours. Maximum: 50 mg/day for children <6 years; 100 mg/day for 6-12 years. IM: 0.5-1 mg/kg every 6-8 hours, not to exceed 50 mg per dose.
Children 2-5 years: 6.25 mg orally every 4-6 hours (max 37.5 mg/day). Children 6-11 years: 12.5-25 mg orally every 4-6 hours (max 150 mg/day). Children ≥12 years: 25-50 mg orally every 4-6 hours (max 300 mg/day).
Initiate at lowest dose (25 mg orally 3-4 times daily) and titrate cautiously due to increased risk of sedation, confusion, and anticholinergic effects. Maximum recommended dose: 100 mg/day in divided doses.
Elderly patients (>65 years): initially 25 mg orally at bedtime, increase if needed; maximum 50 mg/day. Avoid as first-line antihistamine due to anticholinergic adverse effects (confusion, falls).
Not recommended for use in neonates or premature infants due to potential association with sudden infant death syndrome (SIDS) and paradoxical CNS excitation.
Causes significant sedation, impairing ability to drive or operate machinery; anticholinergic effects may exacerbate narrow-angle glaucoma, urinary retention, hyperthyroidism, hypertension, and prostatic hypertrophy; avoid concurrent use with alcohol or other CNS depressants.
Hypersensitivity to diphenhydramine or any antihistamine; acute asthma attack; concurrent MAOI therapy; breastfeeding (large doses may decrease milk production and cause infant sedation); narrow-angle glaucoma (absolute); urinary retention (absolute).
Hydroxyzine may be taken with or without food. Grapefruit juice may increase hydroxyzine serum concentrations and risk of adverse effects; avoid concurrent consumption. High-fat meals can delay but not significantly reduce absorption. No other food restrictions are required.
No significant food interactions. Grapefruit juice may theoretically inhibit CYP2D6 metabolism, but clinical relevance is minimal. Avoid alcohol due to additive CNS depression.
Hydroxyzine is excreted into breast milk in small amounts. The milk-to-plasma ratio is estimated at approximately 0.5. In infants, it may cause sedation, irritability, or poor feeding. Because of the potential for serious adverse reactions in nursing infants, consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for hydroxyzine and any potential adverse effects on the breastfed infant. Alternatives with better safety profiles may be preferred.
Breastfeeding safety: Compatible, but caution advised due to potential for sedation and irritability in the infant. M/P ratio: Not clinically established; oral bioavailability is low but infant exposure is minimal at typical maternal doses. Avoid use in nursing mothers if alternative antihistamines with better safety profiles are available.
Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma albumin, and altered hepatic metabolism) may affect hydroxyzine concentrations. However, specific dose adjustments for pregnancy are not well-established. Clinical monitoring for efficacy and adverse effects is recommended, and using the lowest effective dose for the shortest duration is prudent. No routine dose adjustment is mandated, but individual patient response should guide therapy.
No specific dosing adjustments recommended based on pregnancy-induced pharmacokinetic changes. However, due to increased volume of distribution and altered hepatic metabolism in pregnancy, some clinicians may use lower starting doses for efficacy. Monitor for excessive sedation and adjust accordingly.
Take hydroxyzine exactly as prescribed and do not exceed the recommended dose.,Avoid driving or operating heavy machinery until you know how hydroxyzine affects you, as it may cause drowsiness or dizziness.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) while taking hydroxyzine.,Notify your doctor if you experience blurred vision, dry mouth, difficulty urinating, or rapid heartbeat.,Do not stop taking hydroxyzine abruptly if using for anxiety; consult your doctor for a taper plan.,Store at room temperature, away from moisture and heat.
Do not drive or operate heavy machinery until you know how this drug affects you, as it causes drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and fall risk.,Dry mouth, blurred vision, and constipation are common; drink water and use sugar-free gum for dry mouth.,If you have difficulty urinating or eye pain, stop the medication and seek medical help.,Do not exceed recommended dose; overdose can cause seizures, hallucinations, or serious heart problems.,Take with food if stomach upset occurs, but avoid grapefruit juice as it may affect drug metabolism.
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Aceprometazine."